Search
for
Sort by
Research 30 of 1000+
- Immune response involving the bulge region in addition to telogen conversion contributes to hair loss in a case of atypical drug-induced hypersensitivity syndrome
- Plasma proteome–driven identification of druggable immune regulators of alopecia areata, validated by transcriptome and single-cell mapping
- An In Situ Chemotherapy Drug Combined with Immune Checkpoint Inhibitor for Chemoimmunotherapy
- Mixing the Old with the New: Drug Repurposing for Immune Deficiency in the Era of Precision Medicine and Pediatric Genomics
- Supplementary Material for: Plasma proteome–driven identification of druggable immune regulators of alopecia areata, validated by transcriptome and single-cell mapping
- Supplementary Material for: Plasma proteome–driven identification of druggable immune regulators of alopecia areata, validated by transcriptome and single-cell mapping
- 1419 Pre-clinical in-vitro assays for high throughput screening of drug candidates for protection and restoration of immune privilege in alopecia areata
- Exploring the Drug Repurposing Versatility of Valproic Acid as a Multifunctional Regulator of Innate and Adaptive Immune Cells
- Drugs targeting the JAK/STAT pathway for the treatment of immune-mediated inflammatory skin diseases: protocol for a scoping review
- Innovative strategies for the discovery of new drugs against alopecia areata: taking aim at the immune system
- Cutaneous signals of immune system disease
- Novel Fish Oil-based Bigel System for Controlled Drug Delivery and its Influence on Immunomodulatory Activity of Imiquimod Against Skin Cancer
- Inactivated COVID-19 Vaccine Induces a Low Humoral Immune Response in a Subset of Dermatological Patients Receiving Immunosuppressants
- Diagnosis and treatment of cutaneous adverse effects of targeted therapy, antibody–drug conjugates, and immunotherapy in cancer patients: a national consensus statement by the Spanish Society of Medical Oncology and the Spanish Academy of Dermatology and Venereology
- Erlotinib-related Severe Hair Loss with Severe Exanthematous Drug Eruption: A Case Report
- Next generation human skin constructs as advanced tools for drug development
- Eyelash trichomegaly: review of congenital, acquired, and drug‐associated etiologies for elongation of the eyelashes
- Advances in Cell-Mediated Drug Delivery for Dermatologic Diseases: Mechanisms and Current Applications
- Performance exploration of multi-gene panels of alopecia areata susceptibility and drug-binding targets
- The interplay of oxidative stress and immune dysfunction in Hashimoto’s thyroiditis and polycystic ovary syndrome: a comprehensive review
- Engineering immune-competent hair follicle microphysiological systems: from organoid assembly to dynamic immune modelling
- BH17 Bridging the gap: identifying dual-targeting therapies for patients with alopecia areata and coexisting immune-mediated inflammatory diseases
- Approved systemic drugs needed for dermatosis like alopecia areata, hidradenitis and vitiligo: A SPIN‐FRT evaluation
- Identification of drug-specific public TCR driving severe cutaneous adverse reactions
- Cyclosporin A: a new drug in the field of canine dermatology
- A case of widespread actinic granuloma with associated drug-induced lupus erythematosus
- BH14 Multiple sclerosis and alopecia areata: drug-induced alopecia areata or coexisting autoimmune phenomena?
- Microneedle Transdermal Drug Delivery Systems for Allergen-Specific Immunotherapy, Skin Disease Treatment, and Vaccine Development
- When bugs and drugs conspire: driving acneiform skin toxicity
- Leflunomide: an unlikely trigger and mechanistically a beneficial drug for alopecia areata